UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 525

Sortiert nach

RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics

Cancer cell, 2015-11, Vol.28 (5), p.666-676

2015

Volltextzugriff (PDF)

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort

Journal of clinical oncology, 2015-03, Vol.33 (9), p.992-999

2015

Volltextzugriff (PDF)

Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine

Cell reports (Cambridge), 2020-05, Vol.31 (5), p.107588-107588, Article 107588

2020

Volltextzugriff (PDF)

Dabrafenib in patients with BRAFV600E -positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

The lancet oncology, 2016-05, Vol.17 (5), p.642-650

2016

Volltextzugriff (PDF)

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs

Cancer cell, 2012-01, Vol.21 (1), p.82-91

2012

Volltextzugriff (PDF)

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3

Cell reports (Cambridge), 2014-04, Vol.7 (1), p.86-93

2014

Volltextzugriff (PDF)

Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non–Small-Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2008-03, Vol.70 (3), p.685-692

2008

Volltextzugriff (PDF)

Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [18F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation

Molecular imaging and biology, 2016-10, Vol.18 (5), p.788-795

2016

Volltextzugriff (PDF)

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

Journal of thoracic oncology, 2017-02, Vol.12 (2), p.194-207

2017

Volltextzugriff (PDF)

Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients

Cell reports (Cambridge), 2016-07, Vol.16 (3), p.631-643

2016

Volltextzugriff (PDF)

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.404-415

2020

Volltextzugriff (PDF)

Outcomes of Stereotactic Ablative Radiotherapy in Patients With Potentially Operable Stage I Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2012-05, Vol.83 (1), p.348-353

2012

Volltextzugriff (PDF)

Navigating Diagnostic and Treatment Decisions in Non‐Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach

The oncologist (Dayton, Ohio), 2021-02, Vol.26 (2), p.e306-e315

2021

Volltextzugriff (PDF)

A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer

BMC cancer, 2023-03, Vol.23 (1), p.247-247, Article 247

2023

Volltextzugriff (PDF)

Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer

PloS one, 2024-07, Vol.19 (7), p.e0293707

2024

Volltextzugriff (PDF)

Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?

The European respiratory journal, 2017-06, Vol.49 (6), p.1601838-1601838

2017

Volltextzugriff (PDF)

Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

Pharmaceutical research, 2022-10, Vol.39 (10), p.2507-2514

2022

Volltextzugriff (PDF)

Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: A case report

Lung cancer (Amsterdam, Netherlands), 2015-02, Vol.87 (2), p.201-203

2015

Volltextzugriff (PDF)

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

Cancer discovery, 2014-05, Vol.4 (5), p.606-619

2014

Volltextzugriff (PDF)

Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies

European journal of nuclear medicine and molecular imaging, 2011-09, Vol.38 (9), p.1636-1647

2011

Volltextzugriff (PDF)

Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial

Radiotherapy and oncology, 2015-10, Vol.117 (1), p.44-48

2015

Volltextzugriff (PDF)

Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer

Journal of clinical oncology, 2012-03, Vol.30 (8), p.e104-e108

2012

Volltextzugriff (PDF)

Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2009-04, Vol.27 (11), p.1836-1843

2009

Volltextzugriff (PDF)

Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study

Future oncology (London, England), 2024-07, p.1-11

Smit, Egbert F.

2024

Volltextzugriff (PDF)

Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2009-04, Vol.27 (12), p.2038-2045

2009

Volltextzugriff (PDF)

1 – 25 von 525

Suche als RSS-Feed

Aktive Filter

KollektionBMJ

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(505)
Mit Volltextzugriff
(485)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(313)
Life Sciences & Biomedicine
(308)
Humans
(282)
Oncology
(233)
Female
(174)
Male
(164)
Middle Aged
(153)
Aged
(144)
Lung Neoplasms - Drug Therapy
(121)
Lung Neoplasms - Pathology
(106)
Lung Cancer
(101)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(100)
Adult
(92)
Respiratory System
(92)
Carcinoma, Non-Small-Cell Lung - Pathology
(77)
Biological And Medical Sciences
(76)
Medical Sciences
(74)
Tumors
(67)
Lung Neoplasms - Genetics
(66)
Carcinoma, Non-Small-Cell Lung - Genetics
(57)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort

Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine

Dabrafenib in patients with BRAFV600E -positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3

Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non–Small-Cell Lung Cancer

Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [18F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Outcomes of Stereotactic Ablative Radiotherapy in Patients With Potentially Operable Stage I Non-Small Cell Lung Cancer

Navigating Diagnostic and Treatment Decisions in Non‐Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach

A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer

Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer

Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?

Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: A case report

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies

Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial

Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer

Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study

Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Non–Small-Cell Lung Cancer

Aktive Filter

Suchergebnisse filtern